T. Rowe Price Associates’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $103M | Sell |
3,170,247
-371,760
| -10% | -$12.1M | 0.01% | 564 |
|
|
2025
Q1 | $134M | Sell |
3,542,007
-424,949
| -11% | -$16M | 0.02% | 508 |
|
|
2024
Q4 | $325M | Sell |
3,966,956
-499,181
| -11% | -$40.9M | 0.04% | 335 |
|
|
2024
Q3 | $510M | Buy |
4,466,137
+1,292,970
| +41% | +$148M | 0.06% | 273 |
|
|
2024
Q2 | $240M | Sell |
3,173,167
-3,014
| -0.1% | -$228K | 0.03% | 390 |
|
|
2024
Q1 | $217M | Buy |
3,176,181
+498,359
| +19% | +$34M | 0.03% | 410 |
|
|
2023
Q4 | $168M | Buy |
2,677,822
+260,170
| +11% | +$16.3M | 0.02% | 438 |
|
|
2023
Q3 | $123M | Buy |
2,417,652
+225,270
| +10% | +$11.5M | 0.02% | 473 |
|
|
2023
Q2 | $109M | Buy |
2,192,382
+2,160,354
| +6,745% | +$108M | 0.02% | 504 |
|
|
2023
Q1 | $1.2M | Buy |
32,028
+1,760
| +6% | +$66K | ﹤0.01% | 1686 |
|
|
2022
Q4 | $1.45M | Buy |
30,268
+21,717
| +254% | +$1.04M | ﹤0.01% | 1591 |
|
|
2022
Q3 | $206K | Sell |
8,551
-5,377
| -39% | -$130K | ﹤0.01% | 2531 |
|
|
2022
Q2 | $303K | Buy |
13,928
+1,220
| +10% | +$26.5K | ﹤0.01% | 2430 |
|
|
2022
Q1 | $307K | Buy |
12,708
+1,127
| +10% | +$27.2K | ﹤0.01% | 2532 |
|
|
2021
Q4 | $276K | Sell |
11,581
-800
| -6% | -$19.1K | ﹤0.01% | 2624 |
|
|
2021
Q3 | $314K | Buy |
12,381
+2,042
| +20% | +$51.8K | ﹤0.01% | 2555 |
|
|
2021
Q2 | $233K | Buy |
+10,339
| New | +$233K | ﹤0.01% | 2662 |
|